ALGS Aligos Therapeutics (ALGS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001799448
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter
What the filings say about ALGS
Activist stakes (13D), 180 days
1 filing
Largest: 5.6% of the class
Aligos Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Aligos Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 72.0% of the 11,025,941 shares held after it.
- No other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Nuechterlein Carole bought about $6.0M of ALGS on Oct 25, 2023, the largest insider purchase at the company on our record; 13 funds added in the latest 13F quarter.1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
-39.5% year over year
below 76% of Pharma & Biotech
Margin
-1106.7% net margin
below 87% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
19.2% of the float short (float per yahoo 2026-10-26) · 14.3 days to cover · settled 2026-09-30
below 68% of Pharma & Biotech
The situation: each line is one rule over one dataset
Lawrence M. Blatt disclosed a 5%+ stake (5.6%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ALGS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-50.1%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ALGS: institutional holders (13F)
13F holdings, latest reported quarter
444,110 sh
$2.6M
412,000 sh
$2.4M
327,237 sh
$1.9M
246,579 sh
$1.4M
177,362 sh
$1.0M
Congress trades in ALGS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Lawrence M. Blatt
Activist 13D · 2026-06-24
5.6%
ALGS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ALGS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$94.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$6.3K position · as of 2026-06-30
0.0%
Avantis U.S. Small Cap Equity Fund
$1.9K position · as of 2026-05-31
0.0%
U.S. MICRO CAP PORTFOLIO
$35.2K position · as of 2026-07-31
0.0%
Fidelity Extended Market Index Fund
$141.4K position · as of 2026-05-31
0.0%
Avantis U.S. Small Cap Equity ETF
$8.1K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
14 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
12
Phase 1
1 active
2
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ALGS financials
Revenue growth
-39.5%
XBRL, annual
Net margin
-1106.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ALGS
| FY Dec 2025 | $2.2M |
| FY Dec 2024 | $3.6M |
| FY Dec 2023 | $6.2M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $0 |
| Mar 2026 | $2.8M |
| Dec 2025 | $169.0K |
| Sep 2025 | $741.0K |
| Jun 2025 | $965.0K |
| Mar 2025 | $311.0K |
| Dec 2024 | $606.0K |
| Sep 2024 | $1.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-2,031%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ALGS
| FY Dec 2025 | -1,107% |
| FY Dec 2024 | -3,634% |
| FY Dec 2023 | -1,416% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | -814.1% |
| Dec 2025 | n/a |
| Sep 2025 | -4,256% |
| Jun 2025 | -1,644% |
| Mar 2025 | +13,855% |
| Dec 2024 | -13,556% |
| Sep 2024 | -1,541% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$94.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ALGS
| FY Dec 2025 | -$82.9M |
| FY Dec 2024 | -$81.2M |
| FY Dec 2023 | -$79.4M |
| FY Dec 2022 | -$80.3M |
| FY Dec 2021 | -$116.6M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity ALGS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt ALGS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-113.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ALGS
| FY Dec 2025 | -196.9% |
| FY Dec 2024 | -415.8% |
| FY Dec 2023 | -89.5% |
| FY Dec 2022 | -66.6% |
| FY Dec 2021 | -63.4% |
| Jun 2026 | -113.6% |
| Mar 2026 | -121.9% |
| Dec 2025 | -196.9% |
| Sep 2025 | -141.8% |
| Jun 2025 | -87.7% |
| Mar 2025 | -60.4% |
| Dec 2024 | -415.8% |
| Sep 2024 | -146.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-75.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ALGS
| FY Dec 2025 | -30.5% |
| FY Dec 2024 | -118.4% |
| FY Dec 2023 | -58.8% |
| FY Dec 2022 | -50.3% |
| FY Dec 2021 | -51.3% |
| Jun 2026 | -75.6% |
| Mar 2026 | -83.9% |
| Dec 2025 | -30.5% |
| Sep 2025 | -87.3% |
| Jun 2025 | -60.9% |
| Mar 2025 | -38.2% |
| Dec 2024 | -118.4% |
| Sep 2024 | -88.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ALGS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-103.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ALGS
| FY Dec 2025 | -152.1% |
| FY Dec 2024 | -101.3% |
| FY Dec 2023 | -73.1% |
| FY Dec 2022 | -63.0% |
| FY Dec 2021 | -59.5% |
| Jun 2026 | -103.6% |
| Mar 2026 | -110.6% |
| Dec 2025 | -152.1% |
| Sep 2025 | -111.7% |
| Jun 2025 | -78.6% |
| Mar 2025 | -71.7% |
| Dec 2024 | -101.3% |
| Sep 2024 | -144.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ALGS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value ALGS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-46.8%
TTM free cash flow over market value at close 2026-10-27
FCF yield ALGS
| FY Dec 2025 | -20.9% |
| FY Dec 2024 | -4.8% |
| FY Dec 2023 | -11.2% |
| FY Dec 2022 | -7.9% |
| FY Dec 2021 | -0.9% |
| Jun 2026 | -38.5% |
| Mar 2026 | -26.9% |
| Dec 2025 | -20.9% |
| Sep 2025 | -19.1% |
| Jun 2025 | -24.5% |
| Mar 2025 | -22.6% |
| Dec 2024 | -4.8% |
| Sep 2024 | -23.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ALGS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.2M | $3.6M | $6.2M | $0 |
| Operating income | -$88.0M | -$89.2M | -$88.1M | -$97.6M |
| Net income | -$24.2M | -$131.2M | -$87.7M | -$96.0M |
| EPS (diluted) | -2.45 | -20.94 | -34.20 | -2.25 |
| Operating cash flow | -$82.5M | -$80.7M | -$79.0M | -$79.4M |
| Cash | $18.3M | $37.0M | $135.7M | $81.3M |
SEC XBRL, fiscal years, as known on 2026-10-28
ALGS Stock Sonar score 4/7 axes
Find similar shapesCompareALGS ranks highest on institutional and government (35th percentile) and risk and compliance (35th), and lowest on growth (24th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ALGS filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 5.6% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
